Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor

F. Chen, Masaomi Yamane, M. Inoue, T. Shiraishi, Takahiro Oto, M. Minami, J. Yanagisawa, T. Fujinaga, T. Shoji, Shinichi Toyooka, M. Okumura, S. Miyoshi, T. Bando, H. Date

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Living-donor lobar lung transplantation (LDLLT) is one of the final options for saving patients with pulmonary complications after hematopoietic stem cell transplantation (HSCT). We retrospectively investigated 19 patients who had undergone LDLLT after HSCT in Japan. Eight patients underwent LDLLT after HSCT in which one of the donors was the same living donor as in HSCT (SD group), while 11 received LDLLT from relatives who were not the HSCT donors (non-SD group). In the SD group, three patients underwent single LDLLT. The 5-year survival rate was 100% and 58% in the SD and non-SD groups, respectively. In the SD group, postoperative immunosuppression was significantly lower than in the non-SD group. Two patients died of infection and one died of post-transplant lymphoproliferative disease (PTLD) in the non-SD group, while only one patient died of PTLD 7 years after LDLLT in the SD group. Hematologic malignancy relapsed in two patients in the non-SD group. For the three single LDLLTs in the SD group, immunosuppression was carefully tapered. In our study, LDLLT involving the same donor as for HSCT appeared to have advantages related to lower immunosuppression compared to LDLLT from relatives who were not the HSCT donors. Living-donor lobar lung transplantation involving the same donor as for hematopoietic stem cell transplantation appears to have advantages related to lower immunosuppression compared to living-donor lobar lung transplantation from relatives who are not the hematopoietic stem cell transplantation donors.

Original languageEnglish
Pages (from-to)1509-1516
Number of pages8
JournalAmerican Journal of Transplantation
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Lung Transplantation
Living Donors
Hematopoietic Stem Cell Transplantation
Immunosuppression
Maintenance
Tissue Donors
Transplants
Hematologic Neoplasms
Japan
Survival Rate

Keywords

  • Hematopoietic stem cell transplantation
  • living-donor lobar lung transplantation
  • lung transplantation
  • same donor

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. / Chen, F.; Yamane, Masaomi; Inoue, M.; Shiraishi, T.; Oto, Takahiro; Minami, M.; Yanagisawa, J.; Fujinaga, T.; Shoji, T.; Toyooka, Shinichi; Okumura, M.; Miyoshi, S.; Bando, T.; Date, H.

In: American Journal of Transplantation, Vol. 11, No. 7, 07.2011, p. 1509-1516.

Research output: Contribution to journalArticle

Chen, F, Yamane, M, Inoue, M, Shiraishi, T, Oto, T, Minami, M, Yanagisawa, J, Fujinaga, T, Shoji, T, Toyooka, S, Okumura, M, Miyoshi, S, Bando, T & Date, H 2011, 'Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor', American Journal of Transplantation, vol. 11, no. 7, pp. 1509-1516. https://doi.org/10.1111/j.1600-6143.2011.03591.x
Chen, F. ; Yamane, Masaomi ; Inoue, M. ; Shiraishi, T. ; Oto, Takahiro ; Minami, M. ; Yanagisawa, J. ; Fujinaga, T. ; Shoji, T. ; Toyooka, Shinichi ; Okumura, M. ; Miyoshi, S. ; Bando, T. ; Date, H. / Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. In: American Journal of Transplantation. 2011 ; Vol. 11, No. 7. pp. 1509-1516.
@article{eea8d9f33e0f4f99b2e3a2cb9d844337,
title = "Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor",
abstract = "Living-donor lobar lung transplantation (LDLLT) is one of the final options for saving patients with pulmonary complications after hematopoietic stem cell transplantation (HSCT). We retrospectively investigated 19 patients who had undergone LDLLT after HSCT in Japan. Eight patients underwent LDLLT after HSCT in which one of the donors was the same living donor as in HSCT (SD group), while 11 received LDLLT from relatives who were not the HSCT donors (non-SD group). In the SD group, three patients underwent single LDLLT. The 5-year survival rate was 100{\%} and 58{\%} in the SD and non-SD groups, respectively. In the SD group, postoperative immunosuppression was significantly lower than in the non-SD group. Two patients died of infection and one died of post-transplant lymphoproliferative disease (PTLD) in the non-SD group, while only one patient died of PTLD 7 years after LDLLT in the SD group. Hematologic malignancy relapsed in two patients in the non-SD group. For the three single LDLLTs in the SD group, immunosuppression was carefully tapered. In our study, LDLLT involving the same donor as for HSCT appeared to have advantages related to lower immunosuppression compared to LDLLT from relatives who were not the HSCT donors. Living-donor lobar lung transplantation involving the same donor as for hematopoietic stem cell transplantation appears to have advantages related to lower immunosuppression compared to living-donor lobar lung transplantation from relatives who are not the hematopoietic stem cell transplantation donors.",
keywords = "Hematopoietic stem cell transplantation, living-donor lobar lung transplantation, lung transplantation, same donor",
author = "F. Chen and Masaomi Yamane and M. Inoue and T. Shiraishi and Takahiro Oto and M. Minami and J. Yanagisawa and T. Fujinaga and T. Shoji and Shinichi Toyooka and M. Okumura and S. Miyoshi and T. Bando and H. Date",
year = "2011",
month = "7",
doi = "10.1111/j.1600-6143.2011.03591.x",
language = "English",
volume = "11",
pages = "1509--1516",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor

AU - Chen, F.

AU - Yamane, Masaomi

AU - Inoue, M.

AU - Shiraishi, T.

AU - Oto, Takahiro

AU - Minami, M.

AU - Yanagisawa, J.

AU - Fujinaga, T.

AU - Shoji, T.

AU - Toyooka, Shinichi

AU - Okumura, M.

AU - Miyoshi, S.

AU - Bando, T.

AU - Date, H.

PY - 2011/7

Y1 - 2011/7

N2 - Living-donor lobar lung transplantation (LDLLT) is one of the final options for saving patients with pulmonary complications after hematopoietic stem cell transplantation (HSCT). We retrospectively investigated 19 patients who had undergone LDLLT after HSCT in Japan. Eight patients underwent LDLLT after HSCT in which one of the donors was the same living donor as in HSCT (SD group), while 11 received LDLLT from relatives who were not the HSCT donors (non-SD group). In the SD group, three patients underwent single LDLLT. The 5-year survival rate was 100% and 58% in the SD and non-SD groups, respectively. In the SD group, postoperative immunosuppression was significantly lower than in the non-SD group. Two patients died of infection and one died of post-transplant lymphoproliferative disease (PTLD) in the non-SD group, while only one patient died of PTLD 7 years after LDLLT in the SD group. Hematologic malignancy relapsed in two patients in the non-SD group. For the three single LDLLTs in the SD group, immunosuppression was carefully tapered. In our study, LDLLT involving the same donor as for HSCT appeared to have advantages related to lower immunosuppression compared to LDLLT from relatives who were not the HSCT donors. Living-donor lobar lung transplantation involving the same donor as for hematopoietic stem cell transplantation appears to have advantages related to lower immunosuppression compared to living-donor lobar lung transplantation from relatives who are not the hematopoietic stem cell transplantation donors.

AB - Living-donor lobar lung transplantation (LDLLT) is one of the final options for saving patients with pulmonary complications after hematopoietic stem cell transplantation (HSCT). We retrospectively investigated 19 patients who had undergone LDLLT after HSCT in Japan. Eight patients underwent LDLLT after HSCT in which one of the donors was the same living donor as in HSCT (SD group), while 11 received LDLLT from relatives who were not the HSCT donors (non-SD group). In the SD group, three patients underwent single LDLLT. The 5-year survival rate was 100% and 58% in the SD and non-SD groups, respectively. In the SD group, postoperative immunosuppression was significantly lower than in the non-SD group. Two patients died of infection and one died of post-transplant lymphoproliferative disease (PTLD) in the non-SD group, while only one patient died of PTLD 7 years after LDLLT in the SD group. Hematologic malignancy relapsed in two patients in the non-SD group. For the three single LDLLTs in the SD group, immunosuppression was carefully tapered. In our study, LDLLT involving the same donor as for HSCT appeared to have advantages related to lower immunosuppression compared to LDLLT from relatives who were not the HSCT donors. Living-donor lobar lung transplantation involving the same donor as for hematopoietic stem cell transplantation appears to have advantages related to lower immunosuppression compared to living-donor lobar lung transplantation from relatives who are not the hematopoietic stem cell transplantation donors.

KW - Hematopoietic stem cell transplantation

KW - living-donor lobar lung transplantation

KW - lung transplantation

KW - same donor

UR - http://www.scopus.com/inward/record.url?scp=79959856311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959856311&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2011.03591.x

DO - 10.1111/j.1600-6143.2011.03591.x

M3 - Article

C2 - 21672149

AN - SCOPUS:79959856311

VL - 11

SP - 1509

EP - 1516

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -